TG Therapeutics is a biotechnology business based in the US. TG Therapeutics shares (TGTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $30.32 – a decrease of 13.12% over the previous week. TG Therapeutics employs 319 staff and has a trailing 12-month revenue of around $264.8 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $30.32 |
|---|---|
| 52-week range | $11.86 - $36.50 |
| 50-day moving average | $24.59 |
| 200-day moving average | $19.23 |
| Wall St. target price | $37.22 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.09 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $29.61 from 2024-11-18
| 1 week (2024-11-13) | -15.16% |
|---|---|
| 1 month (2024-10-18) | 27.03% |
| 3 months (2024-08-20) | 19.83% |
| 6 months (2024-05-20) | 79.67% |
| 1 year (2023-11-20) | 130.97% |
|---|---|
| 2 years (2022-11-18) | 271.52% |
| 3 years (2021-11-19) | 21.30% |
| 5 years (2019-11-20) | 279.62% |
| Revenue TTM | $264.8 million |
|---|---|
| Operating margin TTM | 14.82% |
| Gross profit TTM | $2.5 million |
| Return on assets TTM | -0.07% |
| Return on equity TTM | -8.05% |
| Profit margin | -5.43% |
| Book value | $1.34 |
| Market Capitalization | $4.8 billion |
TTM: trailing 12 months
We're not expecting TG Therapeutics to pay a dividend over the next 12 months.
TG Therapeutics's shares were split on a 100:5625 basis on 29 April 2012 . So if you had owned 5625 shares the day before before the split, the next day you'd have owned 100 shares. This wouldn't directly have changed the overall worth of your TG Therapeutics shares – just the quantity. However, indirectly, the new 5525% higher share price could have impacted the market appetite for TG Therapeutics shares which in turn could have impacted TG Therapeutics's share price.
Over the last 12 months, TG Therapeutics's shares have ranged in value from as little as $11.86 up to $36.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TG Therapeutics's is 2.193. This would suggest that TG Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
TG Therapeutics, Inc. , a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S. A.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.